Skip to main content

High-Potency Topical Corticosteroids

Topical corticosteroids are first-line conservative treatment for symptomatic phimosis in boys and for genital lichen sclerosus (LS/BXO), and are used for several other genital dermatoses.[1][2][4][7] Potency is condition-specific: potent / ultrapotent treatment is appropriate for LS and selected genital lichen planus; genital psoriasis and uncomplicated dermatitis generally start with lower-potency agents. Intralesional triamcinolone is a separate route discussed in its companion page.[1][2][3][4]

For related agents, see Topical calcineurin inhibitors, Intralesional corticosteroids, Platelet-rich plasma, and the clinical Lichen sclerosus article.

Potency classification and genital prescribing principles​

The US 7-class potency system governs appropriate genital prescribing. Genital skin is thin and highly absorptive; potency selection must balance efficacy against atrophy risk.[5][6]

US classPotencyAgents used in urology
I — Super-highVery highClobetasol propionate 0.05%, halobetasol propionate 0.05%[5]
II — HighHighBetamethasone dipropionate 0.05% ointment, fluocinonide 0.05%, desoximetasone 0.25%[5]
III–V — MediumMediumBetamethasone valerate 0.1%, mometasone furoate 0.1%, triamcinolone acetonide 0.1%, fluticasone propionate 0.05%[5]
VI–VII — LowLowHydrocortisone 1–2.5%, desonide 0.05%, alclometasone 0.05%[5]

Core genital-use principles:

  • AAFP and AAD classify the genitalia as thin-skin sites with enhanced percutaneous absorption[5]
  • Low-potency agents (VI–VII) are an option for genital psoriasis and routine contact dermatitis; for penile psoriasis, BASHH 2026 recommends moderate-potency topical steroids initially (Grade 1C).[5][38]
  • High-potency agents (I–II) are reserved for specific conditions, lichen sclerosus and lichen planus, where benefit clearly outweighs atrophy risk
  • Ointments are often preferred for LS because of barrier support and fewer potential irritants; check the actual vehicle, since formulations differ[5][7]

Phimosis — the primary urologic application​

Guideline positioning​

The EAU 2026 paediatric guideline gives a strong recommendation to offer topical corticosteroid (ointment or cream) as first-line treatment for symptomatic phimosis. It describes 0.05–0.1% applied twice daily for four to eight weeks with success above 80% and recurrence up to 17%, notes that lower-class steroids may be almost equally effective, and advises continued daily retraction afterward. Physiological non-retractability and preputial adhesions need no treatment unless symptomatic (adhesions do not respond to steroid), and forced retraction is avoided. Selected infants at increased UTI risk from vesicoureteral reflux or posterior urethral valves are an exception, and the guideline recommends treating asymptomatic phimosis in them .[35]

Dual mechanism​

  1. Anti-inflammatory: phospholipase-A2 inhibition leads to reduced prostaglandins and leukotrienes and to decreased edema, fibrin, capillary dilation and fibroblast proliferation
  2. Tissue remodeling: inhibition of epidermal proliferation and collagen synthesis leads to skin thinning and increased elasticity, allowing the stenotic preputial ring to stretch[1]

Cochrane 2024 — 14 RCTs, n = 1,459[1]​

OutcomeEffect vs placebo or no treatmentRR (95% CI)
Complete resolution (4–8 wk; 10 RCTs, n = 834)+436 per 1,000RR 2.73 (1.79–4.16)
Partial resolution (4–8 wk; 7 RCTs, n = 745)+202 per 1,000RR 1.68 (1.17–2.40)
Long-term complete resolution (≥6 mo; 2 RCTs, n = 280)+528 per 1,000RR 4.09 (2.80–5.97)
Adverse effectsToo imprecise to establish a differenceRR 0.28 (0.03–2.62)

Subgroup analysis suggested topical corticosteroids may be more effective in boys younger than three years (versus those aged three years or older); certainty of evidence was low across outcomes.[1]

Which corticosteroid is best — Sridharan 2021 network meta-analysis​

The network meta-analysis ranked several agents favorably and its authors favored hydrocortisone.[8] A 2025 network meta-analysis of 17 RCTs (n = 2,057 boys) found improved partial or complete resolution with each potency class versus control, with no between-class superiority detected; evidence for the moderate-potency class was graded moderate certainty.[48]

Yang 2005 head-to-head RCT. Betamethasone valerate 0.06% versus clobetasone butyrate 0.05%: response (>2-point retractibility-score improvement) rates 81.3% versus 77.4% (p = 0.63).[9]

Campos 2026 multicenter cohort — n = 235​

Across 12 hospitals, 161/235 children assessed at 8–16 weeks after starting betamethasone 0.05% BID for 8 weeks reached Kikiros grade 0–1 (68.5%); 148/383 eligible children were excluded from analysis, including 119 who missed follow-up and 24 who stopped treatment (seven because of preputial irritation). No statistically significant age- or severity-group difference was found, and recurrence was not assessed. Preputial appearance was associated with response: resolution was 151/211 (72%) with normal skin, 8/17 (47%) with a preputial crack, and 2/7 (29%) with a small white scar (p = 0.007 across groups). Suspected or confirmed BXO was excluded. Adherence, age, symptoms, and prior balanitis were not predictive.[10]

Adult phimosis — thinner literature​

Lygas 2022 systematic review found significant heterogeneity and limited trial data. Topical steroids appear probably safe with some potential to reduce LS-associated phimosis signs / symptoms, but good-quality RCT data with patient-reported outcomes are needed.[11]

Standard phimosis protocol[1][9][10]​

ParameterRecommendation
AgentBetamethasone 0.05% topical preparation (used in a pediatric multicenter cohort)[10]
ApplicationThin layer to the stenotic distal prepuce
TechniqueGently retract the foreskin as far as possible without pain, apply to the narrow preputial ring, then return the foreskin over the glans to prevent paraphimosis.[35]
FrequencyTwice daily
Duration4–8 weeks (most protocols use 8 weeks)
Post-treatmentContinue gentle retraction exercises and hygiene after course completion
Partial responseMay repeat a second 4–8-week course
Failure / refractoryRefer for surgical assessment; discuss circumcision or preputioplasty according to anatomy and LS status. The EAU 2026 guideline strongly recommends against simple circumcision when phimosis coexists with buried penis, congenital penile curvature, epispadias, or hypospadias.[35]
Expected successCampos: 161/235 (68.5%) follow-up completers reached Kikiros grade 0–1 at 8–16 weeks; Yang: 81.3% response to betamethasone valerate 0.06% meant >2-point retractibility-score improvement, a different endpoint[10][9]

Lichen sclerosus / BXO — the most important chronic indication​

Overview​

LS is a chronic inflammatory dermatosis predominantly affecting the anogenital region. In males it is called balanitis xerotica obliterans (BXO) and typically involves the foreskin and glans, causing phimosis, meatal stenosis, and potentially urethral stricture. In boys with BXO, the reported average age is 8 years (range 1–16); BXO is an important cause of pathologic phimosis in boys.[12][7]

First-line — ultrapotent / potent topical corticosteroids​

The German S3 guideline (2025; published 2026) recommends potent or ultrapotent topical corticosteroids for genital LS in women, men, girls, and boys; ACOG Practice Bulletin 224 addresses vulvar LS; the British Association of Dermatologists gives age- and sex-specific ultrapotent-steroid regimens; and the Cochrane review reports limited RCT evidence for clobetasol and mometasone.[13][3][14][40] Clobetasol propionate 0.05% ointment is the most studied and widely used agent.[13]

Cochrane 2011 review — Chi et al., 7 RCTs, n = 249[14][15]​

  • Clobetasol 0.05% versus placebo: participant-rated improvement RR 2.85 (95% CI 1.45–5.61); investigator-rated SMD 5.74 (95% CI 4.26–7.23)[14]
  • Mometasone versus placebo: improved clinical grade of phimosis (SMD −1.04; 95% CI −1.77 to −0.31)[14]
  • Topical testosterone, DHT, and progesterone showed no benefit; topical testosterone worsened symptoms when used as maintenance after clobetasol
  • In one 12-week RCT of 38 women with vulvar LS, pimecrolimus and clobetasol showed no detected difference in pruritus or burning/pain; clobetasol improved investigator-rated gross appearance more (SMD −1.64; 95% CI −2.40 to −0.87).[14]

Male-genital LS conservative management — Shieh 2024 systematic review​

Across 17 studies of histologically confirmed penile / urethral LS:[2]

  • Topical corticosteroids remain the mainstay of conservative management
  • Tacrolimus is a selected second-line option when corticosteroids are insufficient or contraindicated[13]
  • PRP and laser remain uncertain: they are not established substitutes for anti-inflammatory care. See the clinical LS evidence comparison, including the large 2026 laser trial and sham-controlled studies[13]

Treatment framework[13][36]​

PhaseRegimenDuration
InductionClobetasol propionate 0.05% ointment, commonly once dailyUsually 1–3 months, adjusted to response and phenotype[36]
TaperReduce application frequency after disease controlIndividualized
MaintenanceOften once/twice weekly proactive treatment or treatment of recurrenceLong-term follow-up[36]
MonitoringFollow-up at 3 months to assess clinical signs, symptoms, application technique and adverse effectsThen every 3–6 months while unstable; at least annually when stable
RefractoryReassess adherence/diagnosis, exclude neoplasia, then specialist-directed escalationSurgery may be required for fixed scarring

Amount and application. Apply the ointment only to skin involved by LS, in a fingertip-unit amount (one fingertip unit covers the whole vulva; the guideline notes a 30 g tube usually lasts about a year of long-term use). Applying it to unaffected skin adds atrophy and irritation without benefit. In a 12-week RCT of 54 women with vulvar LS, tapering regimens of mometasone furoate 0.1% and clobetasol propionate 0.05% ointment each produced 24/27 treatment responders.[49] EuroGuiDerm notes that potent mometasone may be preferred over ultrapotent clobetasol in children and during pregnancy.[36] Add emollients. Ask every LS patient about voiding. New voiding symptoms warrant urology or urogynecology assessment with uroflowmetry; obtain a retrograde urethrogram when the flow pattern is obstructive or meatal stenosis is evident, to assess for distal stricture.[36]

Adherence was associated with outcomes. In a single-center prospective cohort of 507 women with vulvar LS on titrated preventive corticosteroid (mean follow-up 4.7 years), VIN or SCC occurred in 0/357 adherent versus 7/150 (4.7%) partially adherent women; scarring or adhesions occurred in 12/357 (3.4%) versus 60/150 (40%), and reversible steroid-induced atrophy in 4/357 (1.1%) versus 3/150 (2.0%).[37]

BXO-specific considerations in males​

  • BXO stage and topical response. In a five-week placebo-controlled trial, phimosis grade improved in 7/17 evaluable boys given 0.05% mometasone; all seven had early or intermediate histology, no advanced cases improved, and all evaluable boys subsequently underwent circumcision.[1][12][41]
  • German S3 guideline 2026. In LS-associated phimosis unresponsive to guideline-conform therapy, the guideline strongly recommends circumcision, suggests complete foreskin removal, and strongly recommends foreskin histopathology to confirm LS/exclude precancer and topical corticosteroid ointment before and after surgery.[13]
  • LS-related meatal stenosis may require wide meatotomy or meatoplasty after guideline-conform topical treatment fails. Assess for urethral extension; the German S3 guideline weakly suggests meatoplasty and weakly suggests against dilation except for palliation.[13] Topical corticosteroid ointment is used before and after surgery.[12][13][36]
  • Long-term surveillance is important; LS carries an increased SCC risk in affected tissue[12][15]

Lichen planus​

Lichen planus is a chronic inflammatory condition. In uncircumcised men, genital LP can cause adhesions and phimosis; in women, erosive vulvovaginal LP can cause scarring, synechiae, and vaginal stenosis.[16][17] For erosive vulvovaginal LP, persistent erosions, raised lesions, or failure of initial steroid treatment warrant biopsy, and long-term specialist follow-up is recommended (Grade 1D).[47]

Treatment​

LineAgent
First-lineClobetasol 0.05% ointment — cutaneous, genital, and mucosal erosive LP[3][16][17]
Erosive vulvar LPIn a prospective cohort, 63/89 women (71%) initially treated with clobetasol 0.05% ointment twice daily were symptom-free while receiving treatment; 10/113 (9%) had complete resolution of clinical signs apart from scarring.[16][42]
Vaginal involvement and synechiaeAssess for vaginal erosions and stenosis; treat active vaginal disease with intravaginal corticosteroid and use dilators as indicated. Defer adhesiolysis until inflammation is controlled, then resume potent topical steroid immediately after surgery. Men may use gentle foreskin retraction to limit adhesions.[43][16]
Second-lineTacrolimus 0.1% — particularly for vulvovaginal LP[3][17]
RefractoryIntralesional corticosteroids; systemic corticosteroids; acitretin; mycophenolate[3][17]
Uncircumcised menBecause genital LP has been reported less often in circumcised men, Le Cleach and Chosidow state that circumcision is usually recommended for uncircumcised men with genital LP; superpotent topical corticosteroids treat active lesions, and surgery is deferred until active lesions have settled.[16] Other guidance considers circumcision for LP confined to the prepuce if medical treatment fails or symptomatic phimosis persists.[4][38]

Genital psoriasis​

In a 354-patient observational cohort at two tertiary referral centers, 224/354 (63%) had current or previous genital involvement; genital psoriasis is often underrecognized because patients are neither questioned nor examined for it.[18][39]

Treatment principles unique to genital skin:[19][18]

  • Warm moist environment enhances drug penetration and irritation / atrophy risk
  • Low-potency corticosteroids (classes VI–VII) are an option for genital psoriasis; for penile psoriasis, BASHH 2026 recommends moderate-potency topical steroids for initial management (Grade 1C).[18][38]
  • Calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus 1%) are off-label steroid-sparing options with short-term evidence in facial, genital and inverse psoriasis; most studies do not isolate genital outcomes[20][18]
  • Vitamin D analogues (calcipotriene) may cause genital irritation; calcitriol better tolerated[18]
  • Proactive maintenance after clearing: twice-weekly low-potency corticosteroid or calcineurin inhibitor to prevent relapse[19]

Zoon balanitis (plasma cell balanitis)​

Zoon balanitis is a chronic inflammatory condition of the glans and prepuce, usually in uncircumcised men, that can have "cayenne-pepper" speckling.[21][22] A 2025 review found signs compatible with male genital LS in 98.5% of evaluable historical Zoon images; assess foreskin scarring, phimosis and meatal narrowing when evaluating a persistent plaque.[38][44] Its appearance overlaps with LS and PeIN/SCC; consider biopsy if a plaque persists with diagnostic uncertainty or neoplasia cannot be excluded.[38]

Treatment hierarchy:

  1. Circumcision. Considered curative[22][23]
  2. Topical corticosteroids. Trimovate cream (clobetasone butyrate, oxytetracycline and nystatin): clinical resolution in 10 of 10 cases in one series; intralesional or topical steroids yielded satisfactory improvement in another[24][23]
  3. Topical calcineurin inhibitors. Tacrolimus 0.1% BID with good results in 4 weeks in a 9-patient series; option for recalcitrant cases[21][25]
  4. Topical mupirocin. Case report of resolution with monotherapy over 3 months[22]

Labial adhesions​

Common in prepubertal girls; topical corticosteroids are an alternative to topical estrogen for symptomatic cases.[26][27]

  • Myers 2006. Betamethasone 0.05% cream achieved complete separation in 68% (13/19); 14 of the 19 girls had previously failed conjugated estrogen, and 85% of the responders separated after a single 4–6-week course[27]
  • Huseynov 2020 classification. Betamethasone valerate 0.1% achieved 100% in type I (2 wk) and 80% in type II (3 wk); ineffective in type III–IV (thick dense adhesions)[28]
  • Mayoglou 2009. In a retrospective review of 151 girls, time to separation was 1.3 mo with betamethasone versus 2.2 mo with topical estrogen; recurrences and reported side effects were fewer in the betamethasone group[29]
  • Dowlut-McElroy 2019 RCT. Lateral traction plus topical estrogen was better than emollient for adhesion severity, but complete resolution rates not different (36% versus 19%; p = 0.21)[30]

NASPAG 2015: for symptomatic labial adhesions, topical estrogen and/or steroid cream is often curative; surgical separation for failures; recurrence common until puberty.[26]

Intralesional and intravesical triamcinolone in urology​

IC/BPS with Hunner lesions​

AUA IC/BPS guideline 2022, Statement 19 (Recommendation; Grade C): if Hunner lesions are present, fulguration with electrocautery and/or triamcinolone injection should be performed. Hunner-lesion treatment appears to be one of the few IC/BPS therapies that can provide months of improvement after a single procedure.[31]

Bladder instillation — negative and comparative data​

  • Cardenas-Trowers 2021 RCT (90 enrolled; 71 completed all six instillations): adding triamcinolone to a heparin–lidocaine–bicarbonate–bupivacaine instillation did not produce a statistically significant improvement over the same instillation without triamcinolone (first-to-sixth OLS change −6.7 vs −5.8; p = 0.31)[32]
  • Moss 2023 RCT (83 women randomized; 70 completed six instillations): Both DMSO plus triamcinolone and BTH groups had lower ICSI scores. At visit 6, 19/30 (63%) versus 9/21 (43%) with available ICSI data met the threshold of at least a 29.5% reduction (p = 0.15).[33]

The 2025 CUA guideline found insufficient evidence to support routine intravesical triamcinolone for IC/BPS; it separately conditionally recommends intralesional injection for Hunner lesions (very low certainty).[46]

See Intralesional corticosteroids and Intravesical IC/BPS agents for the broader instillation framework.

Adverse effects on genital skin​

Thin skin and occlusion increase absorption, but risk depends on the formulation, amount, site and duration. Correctly supervised LS therapy is generally well tolerated.[5][6][13]

Adverse effectMain considerationClinical significance
Skin atrophyPotency, amount, duration and occlusionMost concerning; worse with higher potency, longer duration, and occlusion
StriaeExcessive/prolonged exposureIrreversible once formed
TelangiectasiaExcessive/prolonged exposureCosmetically concerning
HypopigmentationLocal effectMore apparent in darker skin tones
Red-scrotum syndromeReassess prolonged exposure and diagnosisPersistent redness after prolonged TCS use
Secondary infectionConsider when symptoms worsenCandida or bacterial superinfection
Contact sensitizationConsider when treatment irritatesUsually vehicle components
HPA-axis suppressionDepends on potency, area, duration and occlusionReported at doses as low as 2 g/day in eczema; 50 g/week is a product ceiling, not a safe genital dose[34]
Folliculitis / acneiform eruptionLocal effectMore common with occlusion

Safety and label boundaries​

The cited US clobetasol ointment label limits treatment to two consecutive weeks and ≤50 g/week, advises against groin application, and does not recommend use in children younger than 12 years. Guideline-directed genital LS treatment is a supervised off-label use, with small site-specific amounts and follow-up; the package ceiling is not a target genital regimen. Potency depends on vehicle and formulation, so the class table is only an orientation.[34][36]

Children are more susceptible to systemic absorption.[34] Assess application technique, skin changes and cumulative exposure.[34]

Second-line — topical calcineurin inhibitors​

For LS, consider a TCI when appropriate corticosteroid therapy is ineffective, contraindicated or not tolerated:[3][14][21]

AgentConcentrationKey advantagesKey disadvantagesBest indications
Tacrolimus ointment0.03%, 0.1%No atrophy; effective for LS, LP, ZoonBurning / stinging; boxed warning: long-term safety unestablished; causality of reported malignancies unprovenSteroid-refractory LS; vulvovaginal LP; Zoon balanitis; psoriasis maintenance[3][13][20][21]
Pimecrolimus cream1%No atrophy; less burning than tacrolimusLess effective than clobetasol for LS (investigator-rated); variable Zoon resultsSelected second-line LS; psoriasis; steroid-sparing[14][20][21]

See Topical calcineurin inhibitors for the dedicated deep-dive.

Prescribing summary by condition​

ConditionFirst-linePotencyRegimenDurationSecond-line
Phimosis (pediatric)Betamethasone 0.05% topical preparation; specify the ester and vehicle when prescribingProduct-dependentBID + gentle retraction4–8 wkRepeat a course for partial response; assess refractory phimosis for circumcision or preputioplasty according to anatomy and LS status.[1][5][10][35]
Phimosis (adult)Consider topical corticosteroid after examining for LS and scarringProduct- and diagnosis-dependentSupervised course with gentle retraction; the pediatric betamethasone schedule is an extrapolationReassess responseFollow LS-specific treatment if present; discuss circumcision or preputioplasty for fixed or refractory narrowing as appropriate[11][13]
Lichen sclerosus / BXOClobetasol 0.05% ointmentISee individualized induction/maintenance framework aboveLong-term follow-upTacrolimus 0.1% when corticosteroids are insufficient or contraindicated; intralesional triamcinolone may be considered for resistant hyperkeratotic lesions in adults after excluding neoplasia, or with foreskin-preserving surgery in boys (not recommended in girls); circumcision for male LS-associated phimosis refractory to topical therapy[3][14][13]
Lichen planus (genital)Clobetasol 0.05% ointmentIErosive vulvar LP: BID; penile LP: once daily for 4 wk, then taper frequency over 8 wk according to responseVariableTacrolimus 0.1%; systemic therapy[16][17][38]
Genital psoriasisVulval disease: mid-potency steroid followed by low potency (hydrocortisone 1–2.5% is a low-potency option); penile disease: moderate-potency steroid initially (BASHH 2026, Grade 1C)VI–VII or III–V, formulation-dependentAdjust duration and frequency to the selected steroid and clinical responseIntermittentCalcineurin inhibitors are off-label steroid-sparing options; calcipotriene may irritate genital skin.[5][18][19][20][38][43]
Zoon balanitisTrimovate cream or clobetasol propionate (BASHH 2026, Grade 1D)Product-dependentOnce or twice dailyVaries with clinical responseTacrolimus 0.1%; refer for circumcision (curative in two men in one series)[23][24][38]
Labial adhesionsBetamethasone 0.05% cream; specify the ester and augmentation statusProduct-dependentBID + lateral traction4–6 wk (may repeat)Topical estrogen; surgical separation[5][27]
Contact dermatitis (genital)Low-to-medium TCSV–VIIBID1–2 wkRemove irritant; emollients
Lichen simplex chronicusMedium-to-high TCSII–IVBIDUntil itch-scratch cycle breaksOral antipruritic; behavioral modification
IC/BPS Hunner lesionsFulguration with electrocautery and/or intralesional triamcinolone[31]—At cystoscopySingle procedure; repeat as needed—

Evidence Summary​

IndicationEvidence and limitsKey source
Phimosis resolutionRCT synthesis; low-certainty resolution and harm estimatesMoreno 2024 Cochrane[1]
Phimosis agent selectionNetwork comparison and head-to-head RCT; no proven universal best agentSridharan 2021[8]; Yang 2005[9]
Severe-phimosis responseObservational cohortCampos 2026 multicenter cohort[10]
LS first-lineShort-term RCTs plus guideline recommendationsChi 2011 Cochrane[14]; German S3 2026[13]; ACOG 224[3]
Male LS conservative managementSystematic review of mainly observational evidenceShieh 2024[2]
Lichen planusReview and observational evidenceLe Cleach 2012[16]
Zoon balanitisSmall case seriesKyriakou 2014[21]; Tang 2001[24]
Labial adhesionsMostly observational treatment comparisonsMyers 2006[27]; Huseynov 2020[28]
IC/BPS Hunner lesions (triamcinolone injection and/or fulguration)Guideline Clemens 2022[31]

Clinical Positioning​

  • Topical corticosteroids are first-line for symptomatic phimosis. Cochrane found improved resolution with low-certainty evidence; comparative studies do not identify a universally preferred potency. Specify the product and concentration, and avoid forced retraction.[1][8][9]
  • Preputial appearance was associated with response. In Campos 2026, resolution at 8–16 weeks occurred in 151/211 with normal skin (72%), 8/17 with a preputial crack (47%), and 2/7 with a small white scar (29%); suspected or confirmed BXO was excluded.[10] The EAU 2026 guideline strongly recommends offering circumcision for BXO or phimosis refractory to treatment.[35]
  • LS needs long-term follow-up and individualized disease control. See the induction/maintenance framework above; reassess fixed scarring and suspicious lesions.[13][36]
  • Ointment for genital LS. The German S3 guideline strongly recommends topical corticosteroid ointment over cream or lotion for LS; ointments provide a barrier effect and can cause less irritation than creams.[5][7][13]
  • Do not use topical testosterone, DHT, or progesterone for LS. Cochrane shows no benefit, and topical testosterone actually worsened symptoms as maintenance after clobetasol.[14]
  • Consider biopsy when diagnosis is uncertain, malignancy is suspected, or standard treatment fails. SCC risk in LS warrants reassessment of atypical or worsening lesions.[13][3]
  • Circumcision can provide lasting resolution of Zoon balanitis. In one series, none of 27 circumcised men had recurrence during three years of follow-up.[45] Medical therapy (Trimovate, tacrolimus) is appropriate if circumcision is declined.[23][24]
  • Symptomatic labial adhesions may be treated with topical estrogen or steroid. The reported faster separation with betamethasone came from retrospective data; asymptomatic adhesions usually need observation.[26][27][29]
  • Genital psoriasis treatment depends on site. Low-potency corticosteroids remain an option; BASHH 2026 recommends moderate-potency topical steroids for initial penile-psoriasis management (Grade 1C). Use calcineurin inhibitors for maintenance when appropriate.[18][38]
  • Use site-specific amounts under supervision. The clobetasol package maximum is not a genital dosing recommendation.[34]
  • Intralesional triamcinolone is the instillation-adjacent indication ; in the Cardenas-Trowers RCT, adding intravesical triamcinolone to a heparin–lidocaine–bicarbonate–bupivacaine instillation did not show a statistically significant difference in OLS score change.[31][32]

See Also​

References​

1. Moreno G, Ramirez C, Corbalán J, et al. "Topical corticosteroids for treating phimosis in boys." Cochrane Database Syst Rev. 2024;1:CD008973. doi:10.1002/14651858.CD008973.pub3

2. Shieh C, Hakam N, Pearce RJ, et al. "Conservative management of penile and urethral lichen sclerosus: a systematic review." J Urol. 2024;211(3):354–363. doi:10.1097/JU.0000000000003804

3. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin Summary, Number 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945

4. Teichman JMH, Mannas M, Elston DM. "Noninfectious penile lesions." Am Fam Physician. 2018;97(2):102–110. PMID 29365226

5. Stacey SK, McEleney M. "Topical corticosteroids: choice and application." Am Fam Physician. 2021;103(6):337–343. PMID 33719380

6. Sidbury R, Alikhan A, Bercovitch L, et al. "Guidelines of care for the management of atopic dermatitis in adults with topical therapies." J Am Acad Dermatol. 2023;89(1):e1–e20. doi:10.1016/j.jaad.2022.12.029

7. Ringel NE, Iglesia C. "Common benign chronic vulvar disorders." Am Fam Physician. 2020;102(9):550–557. PMID 33118795

8. Sridharan K, Sivaramakrishnan G. "Topical corticosteroids for phimosis in children: a network meta-analysis of randomized clinical trials." Pediatr Surg Int. 2021;37(8):1117–1125. doi:10.1007/s00383-021-04906-1

9. Yang SS, Tsai YC, Wu CC, Liu SP, Wang CC. "Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study." J Urol. 2005;173(4):1361–1363. doi:10.1097/01.ju.0000156556.11235.3f

10. Campos JM, Ceballos V, Torres AF, et al. "Topical steroids are effective even in severe phimosis: evidence from a multicenter cohort." J Pediatr Surg. 2026;61(7):163093. doi:10.1016/j.jpedsurg.2026.163093

11. Lygas A, Joshi HB. "An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis: a systematic review of the evidence." Expert Opin Pharmacother. 2022;23(9):1115–1122. doi:10.1080/14656566.2022.2075697

12. Nguyen ATM, Holland AJA. "Balanitis xerotica obliterans: an update for clinicians." Eur J Pediatr. 2020;179(1):9–16. doi:10.1007/s00431-019-03516-3

13. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." J Dtsch Dermatol Ges. 2026;24(4):566–584. doi:10.1111/ddg.70000

14. Chi CC, Kirtschig G, Baldo M, et al. "Topical interventions for genital lichen sclerosus." Cochrane Database Syst Rev. 2011;(12):CD008240. doi:10.1002/14651858.CD008240.pub2

15. Chi CC, Kirtschig G, Baldo M, et al. "Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus." J Am Acad Dermatol. 2012;67(2):305–312. doi:10.1016/j.jaad.2012.02.044

16. Le Cleach L, Chosidow O. "Lichen planus." N Engl J Med. 2012;366(8):723–732. doi:10.1056/NEJMcp1103641

17. Usatine RP, Tinitigan M. "Diagnosis and treatment of lichen planus." Am Fam Physician. 2011;84(1):53–60. PMID 21766756

18. Menter A, Korman NJ, Elmets CA, et al. "Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions." J Am Acad Dermatol. 2011;65(1):137–174. doi:10.1016/j.jaad.2010.11.055

19. Armstrong AW, Read C. "Pathophysiology, clinical presentation, and treatment of psoriasis: a review." JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006

20. Amiri D, Schwarz CW, Gether L, Skov L. "Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review." Acta Derm Venereol. 2023;103:adv00890. doi:10.2340/actadv.v103.6525

21. Kyriakou A, Patsatsi A, Patsialas C, Sotiriadis D. "Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature." Dermatology. 2014;228(1):18–23. doi:10.1159/000357153

22. Lee MA, Cohen PR. "Zoon balanitis revisited: report of balanitis circumscripta plasmacellularis resolving with topical mupirocin ointment monotherapy." J Drugs Dermatol. 2017;16(3):285–287. PMID 28301626

23. Yoganathan S, Bohl TG, Mason G. "Plasma cell balanitis and vulvitis (of Zoon): a study of 10 cases." J Reprod Med. 1994;39(12):939–944. PMID 7884748

24. Tang A, David N, Horton LW. "Plasma cell balanitis of Zoon: response to Trimovate cream." Int J STD AIDS. 2001;12(2):75–78. doi:10.1258/0956462011916811

25. Moreno-Arias GA, Camps-Fresneda A, Llaberia C, Palou-Almerich J. "Plasma cell balanitis treated with tacrolimus 0.1%." Br J Dermatol. 2005;153(6):1204–1206. doi:10.1111/j.1365-2133.2005.06945.x

26. Bacon JL, Romano ME, Quint EH. "Clinical recommendation: labial adhesions." J Pediatr Adolesc Gynecol. 2015;28(5):405–409. doi:10.1016/j.jpag.2015.04.010

27. Myers JB, Sorensen CM, Wisner BP, et al. "Betamethasone cream for the treatment of pre-pubertal labial adhesions." J Pediatr Adolesc Gynecol. 2006;19(6):407–411. doi:10.1016/j.jpag.2006.09.005

28. Huseynov M, Hakalmaz AE. "Labial adhesion: new classification and treatment protocol." J Pediatr Adolesc Gynecol. 2020;33(4):343–348. doi:10.1016/j.jpag.2020.03.005

29. Mayoglou L, Dulabon L, Martin-Alguacil N, Pfaff D, Schober J. "Success of treatment modalities for labial fusion: a retrospective evaluation of topical and surgical treatments." J Pediatr Adolesc Gynecol. 2009;22(4):247–250. doi:10.1016/j.jpag.2008.09.003

30. Dowlut-McElroy T, Higgins J, Williams KB, Strickland JL. "Treatment of prepubertal labial adhesions: a randomized controlled trial." J Pediatr Adolesc Gynecol. 2019;32(3):259–263. doi:10.1016/j.jpag.2018.10.006

31. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

32. Cardenas-Trowers OO, Abraham AG, Dotson TK, et al. "Bladder instillations with triamcinolone acetonide for interstitial cystitis–bladder pain syndrome: a randomized controlled trial." Obstet Gynecol. 2021;137(5):810–819. doi:10.1097/AOG.0000000000004348

33. Moss NP, Chill HH, Sand PK, et al. "A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS)." Neurourol Urodyn. 2023;42(3):615–622. doi:10.1002/nau.25142

34. DailyMed. Clobetasol propionate ointment USP 0.05% prescribing information. Label. Accessed September 12, 2026.

35. EAU. Paediatric Urology: Phimosis and Other Abnormalities of the Penile Skin (2026). Guideline.

36. EuroGuiDerm. Guideline on Lichen Sclerosus (2023), topical corticosteroid dosage and maintenance. Guideline. Accessed September 12, 2026.

37. Lee A, Bradford J, Fischer G. "Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women." JAMA Dermatol. 2015;151(10):1061–1067. doi:10.1001/jamadermatol.2015.0643

38. Edwards SK, Shashidharan P, Fernando I, et al. "BASHH national guideline on the management of balanoposthitis (and related penile skin conditions) 2026." Int J STD AIDS. 2026;37(9):969–983. doi:10.1177/09564624261452757

39. Ryan C, Sadlier M, De Vol E, et al. "Genital psoriasis is associated with significant impairment in quality of life and sexual functioning." J Am Acad Dermatol. 2015;72(6):978–983. doi:10.1016/j.jaad.2015.02.1127

40. Lewis FM, et al. "British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018." Br J Dermatol. 2018;178(4):839–853. doi:10.1111/bjd.16241

41. Kiss A, Csontai A, Pirót L, Nyirády P, Merksz M, Király L. "The response of balanitis xerotica obliterans to local steroid application compared with placebo in children." J Urol. 2001;165(1):219–220. doi:10.1097/00005392-200101000-00062

42. Cooper SM, Wojnarowska F. "Influence of treatment of erosive lichen planus of the vulva on its prognosis." Arch Dermatol. 2006;142(3):289–294. doi:10.1001/archderm.142.3.289

43. van der Meijden WI, Boffa MJ, ter Harmsel B, et al. "2021 European guideline for the management of vulval conditions." J Eur Acad Dermatol Venereol. 2022;36(7):952–972. doi:10.1111/jdv.18102

44. Watchorn RE, Doyle C, Kravvas G, Bunker CB. "Zoon balanitis: not a distinct clinicopathological entity?" Clin Exp Dermatol. 2025;50(4):731–739. doi:10.1093/ced/llae457

45. Kumar B, Sharma R, Rajagopalan M, Radotra BD. "Plasma cell balanitis: clinical and histopathological features--response to circumcision." Genitourin Med. 1995;71(1):32–34. doi:10.1136/sti.71.1.32

46. Doiron RC, Tadayon B, Violette PD, et al. "2025 Canadian Urological Association guideline: Selected treatment recommendations for interstitial cystitis/bladder pain syndrome." Can Urol Assoc J. 2025;19(4):90–103. doi:10.5489/cuaj.9182

47. Edwards SK, Lewis F, Fernando I, Haddon L, Grover D. "2024 British Association for Sexual Health and HIV (BASHH) UK national guideline on the management of vulval conditions." Int J STD AIDS. 2025;36(5):346–371. doi:10.1177/09564624241311629

48. Shanmugham S, Lee EL, Kumar S, et al. "Effectiveness of low to moderate potency topical corticosteroids for phimosis resolution in children: results of a network meta-analysis." Int Urol Nephrol. 2025;57(1):9–17. doi:10.1007/s11255-024-04184-5

49. Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. "First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability." Br J Dermatol. 2014;171(2):388–396. doi:10.1111/bjd.12910